Supernus Pharmaceuticals Inc Q1 2025 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Stacy Ku - TD Cowen - Analyst : Hey, good afternoon. Thanks for taking my questions. So the first is on Qelbree. Just how much of the normal seasonality or Q1 dynamics impact Qelbree net pricing this quarter and how should we think about the jump to Q2 remainder of the year in terms of gross to nets? And then maybe could you comment on the level of comfort you might have run [KELPER] consensus around $290 million for the year? That's kind of the first question. And then the second question is on ONAPGO. As we think about the infrastructure required, maybe talk about the plumbing to make sure all start forms can be transformed into patient prescriptions, getting patients on drug. What are your thoughts on the timing to go from a start form to getting on ONAPGO to the patient? So thanks so much.

Question: Stacy Ku - TD Cowen - Analyst : Sure. Thank you so much.

Question: David Amsellem - Piper Sandler Companies - Analyst : Thanks. So just a couple for me. First, on APCO, I know these are early days, but what are you hearing in the field regarding competitive dynamics versus the [ALIV], the [ABBIE] product? And specifically, are you getting any pushback regarding the use of apomorphine in general when there is another [subcube pump] available that delivers Levodopa and Carbidopa. So that's number one. Just talk to the competitive dynamics and what you are seeing and expect to see. And then just turning to the pipeline on 443, I know you're going to disclose a lead indication by the end of this year, but since it is a stimulant, is it fair to say that sleep-wake could be on the table here, either narcolepsy or idiopathic hypersomnia or both? And how are you just thinking about that in terms of its fit for what you plan to do with that asset. Thank you.

Question: David Amsellem - Piper Sandler Companies - Analyst : Okay. Thank you.